Primary Progressive Multiple Sclerosis Clinical Trial
Official title:
Investigating Cortical Gray Matter Demyelination in Primary Progressive Multiple Sclerosis at 7 Tesla
Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS. To date, it is unknown why some people progress immediately from MS onset. The present study will assess the role of gray matter in PPMS by characterizing it with ultra-high field magnetic resonance imaging (MRI). While both white and gray matter are affected in relapsing MS, in PPMS tissue damage is primarily in the cortex. Cortical gray matter consists largely of neuronal cell bodies, which send electrical signals to create a functional response, such as arm or leg movement. While white matter damage slows the signal response, cortical damage inhibits the initial creation of electrical signals. There is a great need to research and develop scientific biomarkers to identify and monitor progression and repair in PPMS. In this project, 7 Tesla MRI is used to investigate the cortical gray matter in people with PPMS. 7 Tesla MRI is the safest and most detailed way to study the brain. Because the cortex is only a few millimeters thick, it has been traditionally difficult to investigate. At 7 Tesla, different layers and lesions within the cortex can be seen. In addition, this project will use myelin-sensitive MRI to determine the biological underpinnings of both cortical lesions and the 'normal appearing' cortical damage in PPMS. This will answer relevant questions about the brain's capacity for repair, the extent of demyelination and the occurrence of inherent cortical remyelination and provides an avenue for the development of novel clinical MR biomarkers tailored to PPMS.
PURPOSE: PPMS presents very differently from relapsing-remitting MS. Spinal cord involvement is greater and motor impairment significantly outweighs sensory symptoms. Contrast-enhancing lesions are infrequent in PPMS. Instead, gray matter atrophy and cortical demyelination occur at greater rates than in relapsing MS. Cortical involvement is prognostically relevant. MRI at standard clinical field strengths (e.g. 1.5 and 3 Tesla) has clear limitations for visualizing cortical damage. In particular, demyelination at the outer cortical layers is underestimated. Although 7 Tesla MRI is known to be superior to clinical MRI, myelin imaging has not yet been widely explored at 7 Tesla. STUDY AIMS: Use anatomical and quantitative MRI at 7 Tesla to identify radiologically visible and invisible features of cortical gray matter damage that contribute to physical and cognitive impairment in PPMS. The specific project aims are 1. to utilize submillimeter anatomical MRI to map the distribution of the different types of cortical lesions in PPMS and assess cortical lesion volume and burden 2. to characterize and compare cortical lesions, perilesional gray and white matter as well as normal appearing gray matter (NAGM) using quantitative MR sequences 3. to explore the relationship between volumetric and myelin-measures with clinical scores in order to determine the best predictor of progression in PPMS RESEARCH PLAN: The investigators will enrol 30 primary-progressive MS subjects and 30 age- and sex-matched healthy controls to participate in two days of MRI experiments. Whole-brain imaging will be performed on both days at Hvidovre Hospital on a research-only 7 Tesla Philips Achieva (Best, The Netherland) with a dual transmit, 32-channel receive head coil (Nova Medical). Day 1: Submillimeter resolution anatomical images are collected for tissue segmentation, lesion identification, the assessment of central veins and paramagnetic rims. In addition, a battery of physical and cognitive testing with a focus in sensorimotor hand function and cognitive processing speed will be performed, assessing two prominent symptoms of PPMS. Day 2: Quantitative, spectroscopic (MRS) and functional MRI (fMRI) for the assessment of myelin. ANALYSIS: The main analysis will consist of cortical lesion identification, segmentation of both lesions and cortex and the assessment of the MRI myelin measures in both the lesions and NAGM. Control data will be used to establish a baseline measure of myelination. Myelin content in the different types of lesions and NAGM will be compared. All statistical analysis will be performed in R. Linear and mixed effects modelling will determine how clinical, structural and MRI measures contribute to physical and cognitive performance, and will allow to extract the most relevant MR predictors of the clinical scores. In part, the analysis will merge the acquired data with data from an ongoing study on structural and functional assessments for sensorimotor function in relapsing-remitting (RRMS) and secondary progressive MS (SPMS) (NCT03653585). This will allow to place the PPMS cohort directly in the context of other subtypes of MS. The present study will significantly enhance the understanding of cortical damage in PPMS, the main contributor to chronic impairment. The non-invasive characterization of cortical lesions, structurally and in terms of myelin, will answer relevant questions about the brain's capacity for repair, the extent of demyelination and the occurrence of inherent cortical remyelination. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Recruiting |
NCT02273635 -
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05029609 -
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
|
Phase 1 | |
Terminated |
NCT03283826 -
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05974839 -
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
|
||
Active, not recruiting |
NCT05974852 -
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
|
||
Recruiting |
NCT05893225 -
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
|
Phase 2 | |
Completed |
NCT03094364 -
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT02253264 -
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
|
Phase 1 | |
Recruiting |
NCT03691077 -
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
|
Phase 3 | |
Completed |
NCT00950248 -
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05232825 -
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT05229861 -
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS
|
N/A | |
Completed |
NCT01077466 -
Natalizumab Treatment of Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01854359 -
Idebenone for Primary Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03493841 -
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
|
Phase 1 | |
Active, not recruiting |
NCT03562975 -
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
|
||
Completed |
NCT00731692 -
FTY720 in Patients With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT04943289 -
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT01776060 -
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
|